• SEC Filings

On May 3, 2018, NuVasive, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”).The Company’s definitive proxy statement for the Annual Meeting was filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 22, 2018 and describes in detail each of the three proposed voting matters (the “Proposals”) submitted to the Company’s stockholders at the Annual Meeting. The final results for the votes cast with respect to each Proposal are set forth below.

As of March 13, 2018, the record date of the Annual Meeting, there were 51,257,817 outstanding shares of the Company’s common stock. At the Annual Meeting, a quorum of 47,159,892 shares of the Company’s common stock were represented in person or by proxy.

Proposal 1

The stockholders elected each of Vickie L. Capps and John A. DeFord, Ph.D. as a Class II director to hold office until the 2021 Annual Meeting of Stockholders, and in each case until their respective successors are duly elected and qualified, by the following vote:

Proposal 2

The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2018 by the following vote:

Proposal 3

The stockholders approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers for the fiscal year ended December31, 2017, as disclosed in the Company’s proxy statement for the Annual Meeting to the compensation disclosure rules of the SEC, by the following vote:

No other items were presented for stockholder approval at the Annual Meeting.

About NuVasive, Inc. (NASDAQ:NUVA)

Nuvasive, Inc. is a medical device company in the spine market. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine. The Company offers two product lines: spine surgery products and biologics. The Company’s spine surgery products line offerings include thoracolumbar product offerings, cervical product offerings, Intra-Operative Monitoring (IOM) services and disposables, which are used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. The Company’s biologics product line offerings includes allograft (donated human tissue), FormaGraft (a collagen synthetic product), Osteocel Plus and Osteocel Pro (each an allograft cellular matrix containing viable mesenchymal stem cells (MSCs)), and AttraX (a synthetic bone graft material), all of which are used to aid the spinal fusion or bone healing process.